Intelligence / Healthtech / New Clinical Trials / Novo Nordisk A/S
Novo Nordisk A/S
18 Nov 2026: Trial registered · Examination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in Adults With Overweight or Obesity, With or Without Type 2 Diabetes. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 18 Nov 2026
- Title
- Examination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in Adults With Overweight or Obesity, With or Without Type 2 Diabetes
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- United States
- Country
- United States
- Reference
- NCT07944118
- Location
- United States
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Novo Nordisk A/S
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Novo Nordisk A/S in our registers.
More from United States
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.